157 related articles for article (PubMed ID: 36359404)
1. Adenovirus-Inspired Virus-Like-Particles Displaying Melanoma Tumor Antigen Specifically Target Human DC Subsets and Trigger Antigen-Specific Immune Responses.
Besson S; Laurin D; Chauvière C; Thépaut M; Kleman JP; Pezet M; Manches O; Fieschi F; Aspord C; Fender P
Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36359404
[TBL] [Abstract][Full Text] [Related]
2. Stimulation of the immune system by a tumor antigen-bearing adenovirus-inspired VLP allows control of melanoma growth.
Besson S; Boucher E; Laurin D; Manches O; Aspord C; Hannani D; Fender P
Mol Ther Methods Clin Dev; 2023 Mar; 28():76-89. PubMed ID: 36620074
[TBL] [Abstract][Full Text] [Related]
3. Unique CLR expression patterns on circulating and tumor-infiltrating DC subsets correlated with clinical outcome in melanoma patients.
Sosa Cuevas E; Valladeau-Guilemond J; Mouret S; Roubinet B; de Fraipont F; Landemarre L; Charles J; Bendriss-Vermare N; Chaperot L; Aspord C
Front Immunol; 2022; 13():1040600. PubMed ID: 36353633
[TBL] [Abstract][Full Text] [Related]
4. BDCA1
Sosa Cuevas E; Ouaguia L; Mouret S; Charles J; De Fraipont F; Manches O; Valladeau-Guilemond J; Bendriss-Vermare N; Chaperot L; Aspord C
Clin Transl Immunology; 2020; 9(11):e1190. PubMed ID: 33282290
[TBL] [Abstract][Full Text] [Related]
5. The melanoma tumor glyco-code impacts human dendritic cells' functionality and dictates clinical outcomes.
Sosa Cuevas E; Roubinet B; Mouret S; Thépaut M; de Fraipont F; Charles J; Fieschi F; Landemarre L; Chaperot L; Aspord C
Front Immunol; 2023; 14():1120434. PubMed ID: 36891308
[TBL] [Abstract][Full Text] [Related]
6. Outer membrane vesicles engineered to express membrane-bound antigen program dendritic cells for cross-presentation to CD8
Schetters STT; Jong WSP; Horrevorts SK; Kruijssen LJW; Engels S; Stolk D; Daleke-Schermerhorn MH; Garcia-Vallejo J; Houben D; Unger WWJ; den Haan JMM; Luirink J; van Kooyk Y
Acta Biomater; 2019 Jun; 91():248-257. PubMed ID: 31003032
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B virus exploits C-type lectin receptors to hijack cDC1s, cDC2s and pDCs.
Ouaguia L; Dufeu-Duchesne T; Leroy V; Decaens T; Reiser JB; Sosa Cuevas E; Durantel D; Valladeau-Guilemond J; Bendriss-Vermare N; Chaperot L; Aspord C
Clin Transl Immunology; 2020; 9(12):e1208. PubMed ID: 33312564
[TBL] [Abstract][Full Text] [Related]
8. Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platform.
Chevillard C; Amen A; Besson S; Hannani D; Bally I; Dettling V; Gout E; Moreau CJ; Buisson M; Gallet S; Fenel D; Vassal-Stermann E; Schoehn G; Poignard P; Dagher MC; Fender P
Mol Ther; 2022 May; 30(5):1913-1925. PubMed ID: 35151843
[TBL] [Abstract][Full Text] [Related]
9. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer.
Huang L; Rong Y; Tang X; Yi K; Qi P; Hou J; Liu W; He Y; Gao X; Yuan C; Wang F
Mol Cancer; 2022 Feb; 21(1):45. PubMed ID: 35148751
[TBL] [Abstract][Full Text] [Related]
10. Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141
Masterman KA; Haigh OL; Tullett KM; Leal-Rojas IM; Walpole C; Pearson FE; Cebon J; Schmidt C; O'Brien L; Rosendahl N; Daraj G; Caminschi I; Gschweng EH; Hollis RP; Kohn DB; Lahoud MH; Radford KJ
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32737142
[TBL] [Abstract][Full Text] [Related]
11. Antigen encoded by vaccine vectors derived from human adenovirus serotype 5 is preferentially presented to CD8+ T lymphocytes by the CD8α+ dendritic cell subset.
Suleman M; Galea S; Gavard F; Merillon N; Klonjkowski B; Tartour E; Richardson J
Vaccine; 2011 Aug; 29(35):5892-903. PubMed ID: 21723900
[TBL] [Abstract][Full Text] [Related]
12. Glyco-Dendrimers as Intradermal Anti-Tumor Vaccine Targeting Multiple Skin DC Subsets.
Duinkerken S; Horrevorts SK; Kalay H; Ambrosini M; Rutte L; de Gruijl TD; Garcia-Vallejo JJ; van Kooyk Y
Theranostics; 2019; 9(20):5797-5809. PubMed ID: 31534520
[TBL] [Abstract][Full Text] [Related]
13. Glycan-Modified Virus-like Particles Evoke T Helper Type 1-like Immune Responses.
Alam MM; Jarvis CM; Hincapie R; McKay CS; Schimer J; Sanhueza CA; Xu K; Diehl RC; Finn MG; Kiessling LL
ACS Nano; 2021 Jan; 15(1):309-321. PubMed ID: 32790346
[TBL] [Abstract][Full Text] [Related]
14. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
[TBL] [Abstract][Full Text] [Related]
15. In vitro priming with adenovirus/gp100 antigen-transduced dendritic cells reveals the epitope specificity of HLA-A*0201-restricted CD8+ T cells in patients with melanoma.
Linette GP; Shankara S; Longerich S; Yang S; Doll R; Nicolette C; Preffer FI; Roberts BL; Haluska FG
J Immunol; 2000 Mar; 164(6):3402-12. PubMed ID: 10706736
[TBL] [Abstract][Full Text] [Related]
16. Cellular immunity induced by a recombinant adenovirus- human dendritic cell vaccine for melanoma.
Naveh HP; Vujanovic L; Butterfield LH
J Immunother Cancer; 2013; 1():19. PubMed ID: 24829755
[TBL] [Abstract][Full Text] [Related]
17. Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in three melanoma models.
Fotaki G; Jin C; Kerzeli IK; Ramachandran M; Martikainen MM; Karlsson-Parra A; Yu D; Essand M
Oncoimmunology; 2018; 7(3):e1397250. PubMed ID: 29399398
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cell biology and its role in tumor immunotherapy.
Wang Y; Xiang Y; Xin VW; Wang XW; Peng XC; Liu XQ; Wang D; Li N; Cheng JT; Lyv YN; Cui SZ; Ma Z; Zhang Q; Xin HW
J Hematol Oncol; 2020 Aug; 13(1):107. PubMed ID: 32746880
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Dendritic Cell Activation by Virus-Based Vaccine Delivery Vectors Emphasizes the Transcriptional Downregulation of the Oxidative Phosphorylation Pathway.
Tsitoura E; Kazazi D; Oz-Arslan D; Sever EA; Khalili S; Vassilaki N; Aslanoglou E; Dérian N; Six A; Sezerman OU; Klatzmann D; Mavromara P
Hum Gene Ther; 2019 Apr; 30(4):429-445. PubMed ID: 30351174
[TBL] [Abstract][Full Text] [Related]
20. Prime-boost immunization by both DNA vaccine and oncolytic adenovirus expressing GM-CSF and shRNA of TGF-β2 induces anti-tumor immune activation.
Kim SY; Kang D; Choi HJ; Joo Y; Kim JH; Song JJ
Oncotarget; 2017 Feb; 8(9):15858-15877. PubMed ID: 28178658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
